SCHEMBL537434

SCHEMBL537434

CCCC[Si](C)(C)CC(N)=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.36
TP53 P04637 2/20 0.36
MEN1 O00255 1/20 0.36
FAAH O00519 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CNR1 P21554 1/20 0.34
CES2 O00748 5/20 0.33
CES1 P23141 5/20 0.33
KDM4E B2RXH2 2/20 0.33
EPHX1 P07099 4/20 0.32
ALOX15 P16050 1/20 0.31
AKR1B1 P15121 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483154 0.93 SOAT1 (0.39) SOAT1TP53MEN1FAAHCYP1A2
SCHEMBL5487758 0.91 SOAT1 (0.42) SOAT1TP53MEN1FAAHCYP1A2
SCHEMBL5487841 0.86 MEN1 (0.30) SOAT1TP53MEN1FAAHCYP1A2
SCHEMBL6047432 0.79 AKR1B1 (0.42) TP53MEN1KMT2ACES2CES1
SCHEMBL5553516 0.76 CES1 (0.37) TP53CA1CES2CES1EPHX1
SCHEMBL30701400 0.74 SOAT1 (0.57) SOAT1TP53MEN1FAAHCYP1A2
SCHEMBL30701337 0.74 SOAT1 (0.57) SOAT1TP53MEN1FAAHCYP1A2
SCHEMBL320488 0.72
SCHEMBL11418684 0.71 TSHR (0.43) MEN1KMT2AALDH1A1
SCHEMBL13663103 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023127857-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME 株式会社理研ジェネシス 2023-07-06 WO disclosed
WO-2022065413-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF 株式会社理研ジェネシス 2022-03-31 WO disclosed
WO-2020203896-A1 NEW ARTIFICIAL NUCLEIC ACID, PRODUCTION METHOD THEREFOR, AND USE THEREOF シスメックス株式会社 2020-10-08 WO disclosed
EP-2415777-B1 PROCESS FOR PRODUCING NUCLEOSIDE TAKEDA PHARMACEUTICAL (JP) 2015-07-29 EP disclosed
US-8653254-B2 Process for producing nucleoside TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-18 US disclosed
US-20120071646-A1 PROCESS FOR PRODUCING NUCLEOSIDE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed
EP-2415777-A1 PROCESS FOR PRODUCING NUCLEOSIDE Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071646-A1 PROCESS FOR PRODUCING NUCLEOSIDE NUDT1, PNP, HPRT1 SOAT1 2356/4885TP53 3673/4885MEN1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.